Literature DB >> 31468341

Mortality After Discontinuation of Primary Care-Based Chronic Opioid Therapy for Pain: a Retrospective Cohort Study.

Jocelyn R James1, JoAnna M Scott2, Jared W Klein3, Sara Jackson3, Christy McKinney4, Matthew Novack4, Lisa Chew3, Joseph O Merrill3.   

Abstract

BACKGROUND: Despite known risks of using chronic opioid therapy (COT) for pain, the risks of discontinuation of COT are largely uncharacterized.
OBJECTIVE: To evaluate mortality, prescription opioid use, and primary care utilization of patients discontinued from COT, compared with patients maintained on opioids.
DESIGN: Retrospective cohort study of patients with chronic pain enrolled in an opioid registry as of May 2010. PARTICIPANTS: Patients with chronic pain enrolled in the opioid registry of a primary care clinic at an urban safety-net hospital in Seattle, WA. MAIN OUTCOMES AND MEASURES: Discontinuation from the opioid registry was the exposure of interest. Pre-specified main outcomes included mortality, prescription and primary care utilization data, and reasons for discontinuation. Data was collected through March 2015. KEY
RESULTS: The study cohort comprised 572 patients with a mean age of 54.9 ± 10.1 years. COT was discontinued in 344 patients (60.1%); 254 (73.8%) discontinued patients subsequently filled at least one opioid prescription in Washington State, and 187 (54.4%) continued to visit the clinic. During the study period, 119 (20.8%) registry patients died, and 21 (3.7%) died of definite or possible overdose: 17 (4.9%) discontinued patients died of overdose, whereas 4 (1.75%) retained patients died of overdose. Most patients had at least one provider-initiated reason for COT discontinuation. Discontinuation of COT was associated with a hazard ratio for death of 1.35 (95% CI, 0.92 to 1.98, p = 0.122) and for overdose death of 2.94 (1.01-8.61, p = 0.049), after adjusting for age and race.
CONCLUSIONS: In this cohort of patients prescribed COT for chronic pain, mortality was high. Discontinuation of COT did not reduce risk of death and was associated with increased risk of overdose death. Improved clinical strategies, including multimodal pain management and treatment of opioid use disorder, may be needed for this high-risk group.

Entities:  

Keywords:  addiction; chronic pain; primary care

Mesh:

Substances:

Year:  2019        PMID: 31468341      PMCID: PMC6854174          DOI: 10.1007/s11606-019-05301-2

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  2 in total

1.  International Stakeholder Community of Pain Experts and Leaders Call for an Urgent Action on Forced Opioid Tapering.

Authors:  Beth D Darnall; David Juurlink; Robert D Kerns; Sean Mackey; Brent Van Dorsten; Keith Humphreys; Julio A Gonzalez-Sotomayor; Andrea Furlan; Adam J Gordon; Debra B Gordon; Diane E Hoffman; Joel Katz; Stefan G Kertesz; Sally Satel; Richard A Lawhern; Kate M Nicholson; Rosemary C Polomano; Owen D Williamson; Heath McAnally; Ming-Chih Kao; Stephan Schug; Robert Twillman; Terri A Lewis; Richard L Stieg; Kate Lorig; Theresa Mallick-Searle; Robert W West; Sarah Gray; Steven R Ariens; Jennifer Sharpe Potter; Penney Cowan; Chad D Kollas; Danial Laird; Barby Ingle; J Julian Grove; Marian Wilson; Kashelle Lockman; Fiona Hodson; Carol S Palackdharry; Roger B Fillingim; Jeffrey Fudin; Jennifer Barnhouse; Ajay Manhapra; Steven R Henson; Bruce Singer; Marie Ljosenvoor; Marlisa Griffith; Jason N Doctor; Kimeron Hardin; Cathleen London; Jon Mankowski; Andrea Anderson; Linda Ellsworth; Lisa Davis Budzinski; Becky Brandt; Greg Hartley; Debbie Nickels Heck; Mark J Zobrosky; Celeste Cheek; Megan Wilson; Cynthia E Laux; Geralyn Datz; Justin Dunaway; Eileen Schonfeld; Melissa Cady; Thérèse LeDantec-Boswell; Meredith Craigie; John Sturgeon; Pamela Flood; Melita Giummarra; Jessica Whelan; Beverly E Thorn; Richard L Martin; Michael E Schatman; Maurice D Gregory; Joshua Kirz; Patti Robinson; James G Marx; Jessica R Stewart; Phillip S Keck; Scott E Hadland; Jennifer L Murphy; Mark A Lumley; Kathleen S Brown; Michael S Leong; Mechele Fillman; James W Broatch; Aaron Perez; Kristine Watford; Kari Kruska; Dokyoung Sophia You; Stacy Ogbeide; Amy Kukucka; Susan Lawson; James B Ray; T Wade Martin; James B Lakehomer; Anne Burke; Robert I Cohen; Peter Grinspoon; Marc S Rubenstein; Stephani Sutherland; Kristie Walters; Travis Lovejoy
Journal:  Pain Med       Date:  2019-03-01       Impact factor: 3.750

2.  The role of opioid prescription in incident opioid abuse and dependence among individuals with chronic noncancer pain: the role of opioid prescription.

Authors:  Mark J Edlund; Bradley C Martin; Joan E Russo; Andrea DeVries; Jennifer B Braden; Mark D Sullivan
Journal:  Clin J Pain       Date:  2014-07       Impact factor: 3.442

  2 in total
  29 in total

Review 1.  Complex Persistent Opioid Dependence with Long-term Opioids: a Gray Area That Needs Definition, Better Understanding, Treatment Guidance, and Policy Changes.

Authors:  Ajay Manhapra; Mark D Sullivan; Jane C Ballantyne; R Ross MacLean; William C Becker
Journal:  J Gen Intern Med       Date:  2020-11-06       Impact factor: 5.128

Review 2.  Opioid Management: Initiating, Monitoring, and Tapering.

Authors:  W Michael Hooten
Journal:  Phys Med Rehabil Clin N Am       Date:  2020-03-11       Impact factor: 1.784

3.  Nonconsensual Dose Reduction Mandates are Not Justified Clinically or Ethically: An Analysis.

Authors:  Stefan G Kertesz; Ajay Manhapra; Adam J Gordon
Journal:  J Law Med Ethics       Date:  2020-06       Impact factor: 1.718

4.  Association between discontinuing chronic opioid therapy and newly diagnosed substance use disorders, accidents, self-inflicted injuries and drug overdoses within the prescribers' health care system: a retrospective cohort study.

Authors:  Corey J Hayes; Erin E Krebs; Chenghui Li; Joshua Brown; Teresa Hudson; Bradley C Martin
Journal:  Addiction       Date:  2021-10-25       Impact factor: 6.526

5.  Exploring perspectives on changing opioid prescribing practices: A qualitative study of community stakeholders in the HEALing Communities Study.

Authors:  Daniel M Walker; Janet E Childerhose; Sadie Chen; Nicolette Coovert; Rebecca D Jackson; Natasha Kurien; Ann Scheck McAlearney; Jaclyn Volney; Daniel P Alford; Julie Bosak; Douglas R Oyler; Laura K Stinson; Melika Behrooz; Mia-Cara Christopher; Mari-Lynn Drainoni
Journal:  Drug Alcohol Depend       Date:  2022-02-02       Impact factor: 4.492

6.  Prescription Opioid Dispensing Patterns Prior to Heroin Overdose in a State Medicaid Program: a Case-Control Study.

Authors:  Daniel M Hartung; Kirbee A Johnston; Sara Hallvik; Gillian Leichtling; Jonah Geddes; Christi Hildebran; Shellie Keast; Brian Chan; P Todd Korthuis
Journal:  J Gen Intern Med       Date:  2020-09-15       Impact factor: 5.128

7.  Medical Record Documentation About Opioid Tapering: Examining Benefit-to-Harm Framework and Patient Engagement.

Authors:  Michele Buonora; Hector R Perez; Jordan Stumph; Robert Allen; Shadi Nahvi; Chinazo O Cunningham; Jessica S Merlin; Joanna L Starrels
Journal:  Pain Med       Date:  2020-10-01       Impact factor: 3.750

8.  Benefits and Harms of Long-term Opioid Dose Reduction or Discontinuation in Patients with Chronic Pain: a Rapid Review.

Authors:  Katherine Mackey; Johanna Anderson; Donald Bourne; Emilie Chen; Kim Peterson
Journal:  J Gen Intern Med       Date:  2020-11-03       Impact factor: 5.128

9.  All-cause mortality among males living with and without HIV initiating long-term opioid therapy, and its association with opioid dose, opioid interruption and other factors.

Authors:  K S Gordon; A Manhapra; S Crystal; J Dziura; E J Edelman; M Skanderson; R D Kerns; A C Justice; J Tate; W C Becker
Journal:  Drug Alcohol Depend       Date:  2020-09-16       Impact factor: 4.492

10.  Association of Dose Tapering With Overdose or Mental Health Crisis Among Patients Prescribed Long-term Opioids.

Authors:  Alicia Agnoli; Guibo Xing; Daniel J Tancredi; Elizabeth Magnan; Anthony Jerant; Joshua J Fenton
Journal:  JAMA       Date:  2021-08-03       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.